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Abstract 
Hepatitis D virus (delta agent) markers were present In 
111 (36%) of 308 Intravenous drug abusers who were 
positive for hepatitis B surface antigen (HBsAg), 52 of 
there having hepatitis D virus antigenaemia. IgM 
antibody ID hepatitis B core antigen (anti-HBc IgM) 
was present in 92 out of 95 subjects tested, indicating 
that hepatitis D virus and hepatitis B virus infections 
had been acquired simultaneously. Hepatitis D virus 
markers were present In three out of four patients with 
fulminant hepatitis, in seven of 11 (64%) with severe 
hepatitis, and in 80 of 223 (36%) with mild or moderate 
hepatitis compared with four of 29 (14%) of those who 
were asymptomatic. These proportional differences 
were significant (p<0.001). Hepatitis D virus markers 
were present in twice as many patients positive for anti-
HBc IgM requiring admission to hospital with 
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acute hepatitis compared with outpatients attending a 
drug treatment centre. Tests on one patient showed 
complete disappearance of HBsAg, but hepatitis D 
antigen (HDAg or delta antigen) and hepatitis B e 
antigen (HBeAg) were still present in serum samples. 
 All five patients with chronic active hepatitis had 
hepatitis D antibody (anti-HD) compared with seven of 
24 (29%) with chronic persistent hepatitis (p = 0.008). 
Blocking anti-HD persisted for long periods after 
simultaneous infections with hepatitis B virus and 
hepatitis D virus but at lower litres than in patients 
with chronic liver disease. 
Introduction 
Superinfection of carriers of hepatitis B virus by hepatitis 
D virus (delta agent) may produce more severe hepatitis 
and lead to chronic active hepatitis and cirrhosis more 
often than with hepatitis B infection alone.1-4 This may 
occur because in a patient with previously established 
hepatitis B virus infection replication of hepatitis D virus 
occurs more quickly, causing a more severe infection than 
in patients with hepatitis B alone.1 Reports from Italy,2 
California,3 and a study of Venezuelan Indians4 have 
shown an increased incidence of hepatitis D virus markers 
in carriers of hepatitis B surface antigen (HBsAg) with 
fulminant hepatitis and in patients progressing to chronic 
active hepatitis and cirrhosis. Studies in the United 
Kingdom,5 Ireland,6-8 Greece,9 Sweden,10 and the United 
States of America,11 however, have suggested that 
simultaneous infection with hepatitis D and hepatitis B 
virus does not necessarily produce increased clinical 
severity compared with hepatitis B virus infection alone. 
 The opportunity to investigate the role of hepatitis D 
virus in exacerbating acute hepatitis when hepatitis B and 
hepatitis D viruses are acquired at roughly the same time 
was provided by a large continuing outbreak of hepatitis B 
and hepatitis D virus infection in drug abusers in Dublin, 
which started in October 1980.12 
 
Patients and methods 
 A total of 308 intravenous drug abusers who were positive for 
HBsAg were examined for hepatitis D virus and hepatitis B virus markers. 
These comprised 148 patients admitted to hospitals in Dublin with acute 
hepatitis and 160 patients who were detected by routine screening of 
outpatients attending the Drug Advisory and Treatment Centre in Dublin. 
 Two hundred and sixty seven patients had acute or asymptomatic 
hepatitis, follow up serum samples were available from 195 of these over a 
period ranging from two months to four years. Serum sample that were 
positive for hepatitis D virus markers (74) and a random sample of those 
negative for hepatitis D virus markers (21) were also tested for anti-HBc IgM, 
Eleven patients were severely ill with transaminase activities greater than 10 
times normal for more than seven days and with raised prothrombin ratios 
(>1.25) and four patients had fulminant hepatitis. Patients in whom illness 
was classified as mild lit moderate (n = 223) had transaminase activities two 
to 10 times normal, while patients classified as asymptomatic (n = 29) 
showed no or only slight increases in transaminase values (< twice normal) 
and cleared HBeAg and HBsAg within normal lengths of time. Forty one 
patients, 40 of whom were from the drug treatment centre, had chronic liver 
disease diagnosed histologically in accordance with the criteria suggested by 
an international group in 1177.13 
 HBsAg and anti-HBs were detected by radioimmunoassay (RIA, 
Abbott Laboratories, Chicago). Hepalitis B e antigen (HBeAg) and anti-HBe 
were detected by enzyme immunoassay.14 Tests for anti-HBc IgM were 
carried out by Dr R Tedder at Middlesex Hospital, London, using 
radioimmunoassay. 
 HDAg and blocking (total) anti-HD were detected by enzyme 
immunoassay using HDAg extracted from serum, as previously described.15 
IgM anti-HD was detected by an IgM class capture enzyme immunoassay, 
also using HDAg extracted from serum. 
 A test for linear trend in proportions was applied to the data on 
patients classified by severity of illness.16 The %2 test with Yates’s correction 
was applied 10 data on patients admitted to hospital and Fisher’s enact rest 
was used on the data on patients with chronic liver disease. 
Results 
 Table I shows the results of tests for hepatitis D virus markers on 303 
drug abusers with hepatitis. B virus markers. Anti-HBc IgM was present in 92 
of 95 patients tested (50 of 51 HDAg positive patients, the one other patient 
positive for HDAg had had acme hepatitis B four months earlier ;IgM 
positive)). Only a single acute phase serum sample was available from 24 of 
the 52 patients positive for HDAg because of either early discharge from 
hospital by the patient or late return to the drug treatment centre. Eight of 
these patients were simultaneously positive for anti-HD IgM. Anti-HBc IgM 
was found in 21 of 23 anti-HD positive patients tested. The mean age of the 
study group was 21’7 years and the male to female ratio was 4.4:1. The male 
to female ratio and the mean ages (data not shown) were similar in those with 
and without hepatitis D virus markers. 
TABLE I— Results of tests for hepatitis D markers on 308 drug abusers with 
hepatitis B markers 
 Total 
(percentage) 
Male Female 
HDAg positive and seroconversions 52 (16.9) 44 8 
Anti-HD positive only 59 (19.1) 48 11 
Hepatitis Dmarker negative 197 (64.0) 160 37 
Total 308 (100) 252 56 
 Serial specimens from 25 patients were available over a mean period 
of 18 months after hepatitis D virus antigenaemia. The mean duration of 
hepatitis D virus antigenaemia was 11 days, range three to 21 days. All 25 
patients developed anti-HD after a mean of 29 days, range 10-60 days; 24 
remained anti-HD positive for the duration of testing (mean 18 months, range 
two months to four years) and one patient became negative after three 
months. Most of these patients had anti-HD litres of < 1/200. 
 Table II gives the results of the clinical analysis of 367 drug 
abusers with acute hepatitis. Differences in the proportion with D 
markers between groups with hepatitis of varying severity was highly 
significant (p<0.001). 
TABLE II—Clinical analysis of 267 drug abusers with hepatitis 
Severity of hepatitis HDV positive 
(percentage) 
HDV 
negative 
Total 
Fulminant 3 (75.0) 1 4 
Severe 7 (63.6) 4 11 
Mild or moderate 80 (35.8) 143 223 
Asymptomatic 4 (13.8) 25 29 
Total 94 (35.2) 173 267 
Z = 3.51, p<0.001 (test for linear trend in proportions).16 
 An analysis of 82 patients who were positive for anti-HBc IgM 
with hepatitis showed that twice as many of those admitted to hospital 
had anti-HD compared with those who attended the drug treatment 
centre—that is, with mild or asymptomatic hepatitis (p<0 1) (table III). 
HDAg positive patients were excluded from this comparison because of 
the relatively transient nature of serum HDAg. 
TABLE III—Hepatitis D virus infection among 82 anti-HBc IgM positive 
drug abusers with hepatitis 
 
Admitted to 
Hospital with 
Clinical 
hepatitis 
Attended drug
Advisory and 
Treatment 
centre only* Total 
Anti-HD positive 41 20 61 
Hepatitis D marker negative 9 12 21 
Total 50 32 82 
%2 = 2.94 (for 1 df with Yates’s correction); p<0.1. 
*With mild or asymptomatic hepatitis. 
 Of four patients with fulminant hepatitis, two died and only one 
had superinfection with hepatitis D virus; two had HDAg and sero-
converted to anti-HD, Neither of the two patients who died had HDAg or 
blocking anti-HD, but one had anti-HD IgM. No serum sample was 
available from the fourth patient for retrospective testing for anti-HD 
IgM and therefore hepatitis D virus could nor be excluded. 
 All five carriers of HBsAg with histologically diagnosed chronic 
active hepatitis had high litres of anri-HD (>1/5000). This incidence was 
significantly different from that in non-HBsAg carriersi with chronic 
liver disease and in those with chronic persistent hepatitis (p= 0008) 
(table IV). 
TABLE IV—Hepatitis D virus markers in 41 drug abusers with chronic 
liver disease 
 Anti-HD 
positive 
(percentage) 
HDV 
negative Total 
Chronic active hepatitis HBsAg carriers 5 (100)*  5 
Chronic active hepatitis or cirrhosis* 5 (42) 7 12 
Chronic active hepatitis, 
asymptomatic HBsAg carriers, or both 7 (29) 17 24 
Total 17 (41) 24 41 
*Non-HBsAg carriers but had hepatitis B markers. 
+p = 0 008 (Fisher’s exact test) compared with other groups of patients 
with chronic liver disease combined. 
 Figure 1 shows the typical serological course found in patients in 
whom HDAg was detected in their serum samples taken in the acute 
phase of simultaneously acquired hepatitis B and hepatitis D virus 
infections. 
 Two patients with hepatitis D virus superinfection and moderate 
hepatitis became hepatitis D virus antigenaemic about five months 
after acute hepatitis B virus infection. In these patients tests 
for HBeAg became negative at the time of hepatitis D virus 
antigenaemia (fig 2). A decrease in the amount of HBsAg 
was also seen in some patients positive for HDAg; in one 
patient with moderate hepatitis HBsAg became completely 
undetectable, hut tests for HDAg and HBeAg remained 
positive and he seroconverted to anti-HD and anti-HBe 18 
days later but remained negative for HBsAg (fig 3). The 
only patient with fulminant hepatitis D virus superinfection 
also showed a decrease in the amount of HBsAg when 
positive for HDAg and in coma five months after acute 
hepatitis B (fig 4). Recovery from coma was accompanied 
by the disappearance of HDAg and a rise in the amount of 
HBsAg in this and one other patient. 
 
Discussion 
 As in Sweden,10 it appears that hepatitis D virus 
infection has only recently been introduced into Ireland 
since hepatitis D virus markers have not been detected in 
scrum samples stored before 1973 (AGS, unpublished data). 
Tests for anti-HBc IgM indicated that most cases of 
hepatitis B in this outbreak were acute and that where 
hepatitis D virus infection also occurred this was acquired 
simultaneously. The number of drug abusers 
in Dublin who were carriers of HBsAg was low at this acute stage 
of the epidemic, which probably accounts for the low incidence of 
hepatitis D virus superinfections recorded in this study. 
 Although we have noted transient anti-HD antibody in 
some patients previously,6 in this study seroconversion to 
blocking anti-HD usually occurred early (mean 29 days) and 
remained positive in 24 of 25 cases for the duration of testing 
(mean 18 months). This contrasts with two Studies that found 
sero-conversion to anti-HD to be transient or absent after 
simultaneously acquired hepatitis D and hepatitis B virus 
infection in three and 20 patients, respectively.17 18 HDAg derived 
from liver was used in these two Studies, whereas HDAg derived 
from serum, which has been found to be more sensitive for the 
detection of anti-HD,15 was used in our study. In most patients 
anti-HD was detectable only at a relatively low dilution (up to 
1/200); whereas, as observed by Smedile et al,17 those 
 
who were positive for anti-HD with chronic liver disease had 
much higher titres (> 1/5000), Sensitivity of the test system is 
therefore more important in detecting anti-HD after acute hepatitis 
D virus infection than in chronic cases. 
 Hepatitis D virus antigenaemia is common in drug abusers 
in Dublin6 12 15 and occurred as the initial marker in 47% of those 
with hepatitis D virus infection in this study. It was found for an 
average of 11 days and for up to three weeks after the time of 
admission 10 hospital. Although this was transient, hepatitis D 
virus antigenaemia cannot be described as rare as reported 
previously.18-20 A high incidence of hepatitis D virus antigenaemia 
has also been found in small groups of Scottish,6 15 Australian,21 
and Swiss22 drug abusers. Enzyme immunoassay may be more 
sensitive than radioimmunoassay for the detection of HDAg,15 23 
which may contribute to the higher incidence found in this study. 
 Rapid and pronounced fluctuations ill concentrations of 
HBsAg were seen in patients with hepatitis D virus antigenaemia 
and, usually, moderate or severe hepatitis. Although a decrease in 
the concentration of HBsAg after hepatitis D virus antigenaemia 
has been reported,10 total loss of HBsAg during hepatitis D virus 
and HBe antigenaemia has not been recorded previously. In one 
patient total loss of HBsAg occurred while HDAg and HBeAg 
remained positive (fig 3), Furthermore, 24 of our patients from 
whom only single specimens were obtained had hepatitis D virus 
antigenaemia, and eight were also positive for anti-HD IgM. If a 
blocking anti-HD test had been the only test used these hepatitis D 
virus infections would have been missed. This and the finding of 
anti-HD IgM alone in one of our fulminant cases suggest that all 
drug abusers with hepatitis should be screened for all three 
hepatitis D virus markers and secondary hepatitis B virus markers. 
 Hepatitis D virus markers occurred in three of four 
(75%) patients with fulminant hepatitis, in seven of 11 
(64%) with severe hepatitis, in 80 of 223 (36%) with mild 
or moderate hepatitis, and in four of 29 (14%) of those with 
asymptomatic hepatitis; these proportional differences were 
highly significant. Furthermore, among 82 patients with 
diagnosed acute or recent hepatitis B infection (anti-HBc 
IgM positive) twice as many of those admitted to hospital 
had hepatitis D virus Infection compared with 
asymptomatic anti-HBc IgM positive patients who attended 
the drug treatment centre. Although this finding was not 
significant at the 5% level (p<0.1), the cumulative findings 
suggest a strong association between simultaneously 
acquired hepatitis D and hepatitis B virus infection and the 
severity of hepatitis. Thus patients with hepatitis D virus 
infection required admission to hospital more often than 
those with hepatitis B virus infection alone. These findings 
are consistent with results of our previous reports,6 7 which 
were confined to patients attending the centre, and provide 
the first evidence confirming that hepatitis D virus can 
cause a more severe acute infection when it is acquired 
simultaneously with hepatitis B virus. 
 Despite the differences in severity and morbidity 
noted above most patients appeared to make a complete 
recovery. Further follow up studies are required to establish 
whether infection with hepatitis D virus during the acute 
phase of hepatitis B virus infection predisposes to the 
development of chronic liver disease. In this study 41 
patients were shown to have chronic liver disease and all 
five carriers of HBsAg with chronic active hepatitis had 
anti-HD in high titre. Furthermore, seven of 24 (29%) drug 
abusers with chronic persistent hepatitis had anti-HD, and 
these are being followed up for possible progression to 
chronic active hepatitis, progression from chronic persistent 
hepatitis to chronic active hepatitis is more common in drug 
abusers than in people who do not use drugs,24 and this 
might be attributable to hepatitis D virus infection. Hepatitis 
non-A, non-B infections also cause chronic liver disease in 
drug abusers,25 making it difficult to assess the contribution 
of each agent to chronic liver disease, Nevertheless, the 
association between hepatitis D virus and chronic active 
hepatitis appears to be established.1 4 1 
 In conclusion, our data suggest that even 
simultaneous infection with hepatitis D virus and hepatitis 
B virus causes increased seventy and morbidity, in addition 
to the acknowledged role of hepatitis D virus in chronic 
liver disease and increased severity after hepatitis D virus 
superinfection. Thus hepatitis D virus infections may lead to 
increased severity in all clinical situations. 
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